Finance

Lists
ANIP:NASDAQ
ANI Pharmaceuticals Inc Common Stock
$74.04
-0.52%
(-0.39) 1D
$74.04
0.00% (0.00)
After hours
Closed: Sep 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANIP...
Open
$74.00
High
$75.50
Low
$73.69
Mkt. cap
1.70B
Avg. vol.
405.04K
Volume
368.80K
P/E ratio
16.06
52-wk high
$96.99
52-wk low
$69.58
EPS
$4.61
Beta
0.45
Shares outstanding
22.96M
No. of employees
970
Open
$74.00
High
$75.50
Low
$73.69
Mkt. cap
1.70B
Avg. vol.
405.04K
Volume
368.80K
P/E ratio
16.06
52-wk high
$96.99
52-wk low
$69.58
EPS
$4.61
Beta
0.45
Shares outstanding
22.96M
No. of employees
970
News stories
From web sources and news partners
About ANI Pharmaceuticals Inc Common Stock
CEO-
Employees970
Founded2001
HeadquartersBaudette, Minnesota, United States
SectorPharmaceutical industry
Websiteanipharmaceuticals.com
Analyst ratings
Based on 8 analysts giving stock ratings to ANIP in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for ANIP in the last 3 months.
Highest
Current $74.04
$121.00 (+63.43%)
Average
$106.75 (+44.18%)
Lowest
$85.00 (+14.80%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Oppenheimer
Hold
Initiated
$85.00
+14.8%
09/23/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
$121.00
+63.4%
09/21/2026
Daniel Clark
Leerink Partners
Buy
Initiated
$104.00
+40.5%
09/09/2026
Glen Santangelo
Barclays
Buy
Maintained
$100.00
+35.1%
08/25/2026
Unknown Analyst
Jefferies
Buy
Reiterated
$120.00
+62.1%
08/10/2026
Ekaterina Knyazkova
J.P. Morgan
Buy
Reiterated
$115.00
+55.3%
08/10/2026
Gary Nachman
Canaccord Genuity
Hold
Maintained
$90.00
+21.6%
08/10/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$119.00
+60.7%
08/07/2026
Les Sulewski
Truist Financial
Hold
Maintained
-
-
05/11/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
-
-
05/08/2026
David Amsellem
Piper Sandler
Buy
Maintained
$111.00
+49.9%
04/23/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$120.00
+62.1%
03/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
227.81M
247.06M
237.46M
266.04M
Cost of goods sold
93.39M
100.27M
93.58M
100.16M
Cost of revenue
93.39M
100.27M
93.58M
100.16M
Research and development expenses
12.30M
12.26M
10.60M
14.75M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
76.26M
82.29M
73.66M
91.66M
Operating expense
111.19M
117.16M
105.17M
126.05M
Total operating expenses
204.58M
217.43M
198.76M
226.21M
Operating income
23.23M
29.63M
38.71M
39.84M
Other non operating income
-
-
-
-
EBT including unusual items
33.80M
31.48M
40.22M
37.10M
EBT excluding unusual items
17.65M
26.07M
34.29M
35.73M
Income tax expense
7.18M
3.99M
10.73M
12.39M
Effective tax rate
21.25%
12.67%
26.68%
33.39%
Other operating expenses
-
-
-
-
Net income
26.62M
27.49M
29.49M
24.71M
Net profit margin
11.68%
11.13%
12.42%
9.29%
Earnings per share
2.04
2.33
2.05
2.21
Interest and investment income
3.55M
3.16M
3.78M
3.86M
Interest expense
-8.28M
-7.57M
-7.55M
-7.50M
Net interest expenses
-4.73M
-4.41M
-3.77M
-3.64M
Depreciation and amortization charges
22.63M
22.61M
20.92M
19.64M
EBITDA
45.86M
52.24M
59.62M
59.48M
Gain or loss from assets sale
295.00K
87.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps